Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment provides home health and hospice services primarily in the Southeast and Texas. Its home health services include a range of Medicare-certified home nursing services to adult patients in need of care comprising skilled nursing, medical social work, and home health aide services, as well as physical, occupational, speech therapy, and others. This segment's hospice services comprise in-home services to terminally ill patients and their families to address patients' physical needs, including pain control and symptom management, and to provide emotional and spiritual support. As of June 14, 2021, it operated 140 hospitals, 250 home health locations, and 93 hospice locations in 42 states and Puerto Rico. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was founded in 1983 and is based in Birmingham, Alabama.
IPO Year:
Exchange: NYSE
Website: encompasshealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2024 | $115.00 | Overweight | KeyBanc Capital Markets |
| 7/10/2024 | $100.00 | Outperform | Leerink Partners |
| 3/6/2024 | $95.00 | Overweight | Barclays |
| 3/14/2023 | $57.00 | Equal Weight | Barclays |
| 2/7/2022 | $90.00 → $80.00 | Strong Buy | Raymond James |
| 11/3/2021 | $94.00 → $80.00 | Buy | Mizuho |
| 11/2/2021 | $107.00 → $90.00 | Strong Buy | Raymond James |
| 10/13/2021 | $100.00 → $88.00 | Buy | Truist Securities |
| 9/24/2021 | $98.00 | Buy | UBS |
| 8/2/2021 | $95.00 → $107.00 | Outperform → Strong Buy | Raymond James |
4 - Encompass Health Corp (0000785161) (Issuer)
KeyBanc Capital Markets initiated coverage of Encompass Health with a rating of Overweight and set a new price target of $115.00
Leerink Partners initiated coverage of Encompass Health with a rating of Outperform and set a new price target of $100.00
Barclays initiated coverage of Encompass Health with a rating of Overweight and set a new price target of $95.00
Barclays initiated coverage of Encompass Health with a rating of Equal Weight and set a new price target of $57.00
Raymond James reiterated coverage of Encompass Health with a rating of Strong Buy and set a new price target of $80.00 from $90.00 previously
Mizuho reiterated coverage of Encompass Health with a rating of Buy and set a new price target of $80.00 from $94.00 previously
Raymond James reiterated coverage of Encompass Health with a rating of Strong Buy and set a new price target of $90.00 from $107.00 previously
Truist Securities reiterated coverage of Encompass Health with a rating of Buy and set a new price target of $88.00 from $100.00 previously
UBS initiated coverage of Encompass Health with a rating of Buy and set a new price target of $98.00
Raymond James upgraded Encompass Health from Outperform to Strong Buy and set a new price target of $107.00 from $95.00 previously